Womed raises more than €7M for US expansion and clinical trials in women's health

Womed, a Montpellier medtech founded in 2018 on the campus of the CNRS, has raised more than €7 million in a round that closed in June 2026 and was publicly announced on 17 July. The financing combines two distinct streams: €5 million from institutional and family-office investors — Irdi Capital Investissement, Cemag (represented by Dr André Ulmann), and Cantrak (via MacNaughton) — and €2.1 million raised through crowdfunding campaigns on Lita and Capital Cell, which together brought in more than twice their combined initial target of €1 million. No stage label is attached to this round.

Womed was founded by Gonzague Issenmann (President), Dr Stéphanie Huberlant (gynaecologist-obstetrician), and Prof. Xavier Garric (CNRS polymer scientist). The founding team combines clinical medicine, polymer materials science, and commercial leadership — a combination that matters in a segment where the translation from laboratory science to cleared medical device is typically where women's health companies stall.

A first product in distribution, a pipeline defined by what it avoids

Womed's first commercial product, Womed Leaf, is a patented intra-uterine polymer device designed to prevent intrauterine adhesions (Asherman's syndrome). The mechanism: the device is deployed as a membrane inside the uterine cavity, where it prevents adhesion formation during healing, then evacuates naturally. No surgical removal is required.

The pipeline extends this logic into higher-prevalence indications. The first development programme targets uterine fibroids — affecting roughly 70% of women at some point in their lives — with a stated aim of treating them without surgery and without hormonal intervention. The second programme addresses acute uterine bleeding. First clinical trials for both are planned from 2027.

The crowdfunding outcome is a useful secondary data point: two campaigns overshooting their combined target by more than 100% signals demand from patients and retail investors independent of institutional appetite. It does not de-risk the clinical programme, but it distinguishes Womed from medtechs whose only validation comes from institutional backers with their own commercial interests.

Expansion with two clocks running simultaneously

The stated priority for international deployment is the United States. No specific timeline for US commercial launch is provided; US market entry for a medtech requires FDA clearance, which runs on a schedule independent of European clinical and commercial operations. Womed's current team of ten employees and ten external consultants is expected to double in headcount by end-2028, toward a capacity of treating up to 95,000 women per year at that horizon.

Running a new clinical programme and opening a new regulatory jurisdiction at the same time is the principal execution risk the €7M+ round needs to cover. The company's framing is measured — it announces a start date for trials and an ambition for US entry, not revenue targets or valuation milestones — which is the right register for a stage where clinical outcomes are not yet known. The 2027 trial results will determine how much of the remainder that framing survives.